title: [Antifibrotic effects of N-acetyl-seryl-aspartyl-lysyl-proline mediated by regulation of transforming growth factor beta and connective tissue growth factor expression on rats with silicosis].
abstract: OBJECTIVE
  To investigate whether the effect of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) on transforming growth factor beta (TGF-beta1) and connective tissues growth factor (CTGF) was involved in AcSDKP's antifibrotic effect on the rats with silicosis.
  
  
  METHODS
  Rats were divided into 6 groups randomly, 10 rats in each group: Control of silicotic model: 1.0 ml normal sodium and was killed after 4 or 8 weeks; Silicotic model 1: 50 mg/ml silica suspension and was killed after 4 weeks; Silicotic model 2: 50 mg/ml silica suspension and was killed after 8 weeks; Anti-fibrosis treatment of AcSDKP: after each rat was intratracheally instilled with 50 mg/ml silica suspension for 4 weeks, AcSDKP 800 microg/(kg x d) was administered into every rat and rats were killed at the 8 weeks; Preventing fibrosis treatment of AcSDKP: after AcSDKP [800 microg/(kg x d)] was administered into every rat for 48 hours, each rat was intratracheally instilled with 50 mg/ml silica suspension and rats were killed at the 8 weeks. Lung fibrosis in morphology was observed by HE staining. The expressions of TGF-beta1 and CTGF in lung were observed by immunohistochemistry. The mRNA expressions of TGF-beta1 and CTGF in lung were observed by real-time PCR.
  
  
  RESULTS
  In anti-fibrosis treatment of AcSDKP group, protein expression of TGF-beta1 and CTGF were (0.244 +/- 0.016) and (0.241 +/- 0.017) respectively, and significantly lower that those in the silicotic model 1 and 2 groups; mRNA expressions of TGF-beta1 and CTGF decreased, mRNA expressions of CTGF were significantly lower that those in the silicotic model 1 and 2 groups (P < 0.05); In preventing fibrosis treatment of AcSDKP group, protein expression and mRNA expression of TGF-beta1 were significantly lower that those in the silicotic model 2 group (P < 0.05).
  
  
  CONCLUSIONS
  AcSDKP can decrease the expressions of TGF-beta1 and CTGF in lung tissues of the rats with experimentally induced pulmonary fibrosis.
authors.affiliation: North China Coal Medical College, Tangshan 063000, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Li
authors.forename: Fang
authors.initials: F
authors.lastname: Yang
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: Zhang
authors.forename: Jing-Bo
authors.initials: JB
authors.lastname: Yan
authors.forename: Ping
authors.initials: P
authors.lastname: Chen
authors.forename: Dan-Dan
authors.initials: DD
authors.lastname: Li
authors.forename: Kun-Fei
authors.initials: KF
authors.lastname: Wu
mesh_terms: D000818:Animals; D055513:Connective Tissue Growth Factor / Q000378:metabolism*; D004195:Disease Models, Animal; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology*; D011658:Pulmonary Fibrosis / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012829:Silicosis / Q000378:metabolism*; D016212:Transforming Growth Factor beta / Q000378:metabolism*
chemical_list: C526316:CCN2 protein, rat; D009842:Oligopeptides; D016212:Transforming Growth Factor beta; D055513:Connective Tissue Growth Factor; C058504:goralatide